Click for best price
Metastatic Cancer Drug Market Size, Share 2022
Metastatic cancer (also referred as advanced or stage 4 cancer) occurs when the primary cancer has spread to other parts of the body via the lymphatic or blood circulation systems. Although it can spread to almost every organ in the body, some cancers, such as breast cancer, can spread to the lungs, liver, bones, and brain.The metastatic cancer drug is supportive and aims to reduce the severity of the symptoms.
This report contains market size and forecasts of Metastatic Cancer Drug in Global, including the following market information:
Global Metastatic Cancer Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Metastatic Cancer Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Trastuzumab Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Metastatic Cancer Drug include AstraZeneca, Merck, Pfizer, Celgene, AKRON, Novartis, Galen, Pacira BioSciences and Johnson & Johnson, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We has surveyed the Metastatic Cancer Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Metastatic Cancer Drug Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Metastatic Cancer Drug Market Segment Percentages, by Type, 2021 (%)
Trastuzumab
Pertuzumab
Global Metastatic Cancer Drug Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Metastatic Cancer Drug Market Segment Percentages, by Application, 2021 (%)
Hospitals
Specialty Clinics
Global Metastatic Cancer Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Metastatic Cancer Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Metastatic Cancer Drug revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Metastatic Cancer Drug revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Merck
Pfizer
Celgene
AKRON
Novartis
Galen
Pacira BioSciences
Johnson & Johnson
Fresenius Kabi AG
Spectrum Pharmaceuticals
Takeda Pharmaceutical
Teva Pharmaceutical Industries
Cipla
Sun Pharmaceutical Industries
Shanghai Fosun Pharmaceutical
Ingenus
| Report Attributes |
Report Details |
| Report Title |
Metastatic Cancer Drug Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
100 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Metastatic Cancer Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Metastatic Cancer Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Metastatic Cancer Drug Overall Market Size
2.1 Global Metastatic Cancer Drug Market Size: 2021 VS 2028
2.2 Global Metastatic Cancer Drug Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Metastatic Cancer Drug Players in Global Market
3.2 Top Global Metastatic Cancer Drug Companies Ranked by Revenue
3.3 Global Metastatic Cancer Drug Revenue by Companies
3.4 Top 3 and Top 5 Metastatic Cancer Drug Companies in Global Market, by Revenue in 2021
3.5 Global Companies Metastatic Cancer Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Metastatic Cancer Drug Players in Global Market
3.6.1 List of Global Tier 1 Metastatic Cancer Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Metastatic Cancer Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Metastatic Cancer Drug Market Size Markets, 2021 & 2028
4.1.2 Trastuzumab
4.1.3 Pertuzumab
4.2 By Type - Global Metastatic Cancer Drug Revenue & Forecasts
4.2.1 By Type - Global Metastatic Cancer Drug Revenue, 2017-2022
4.2.2 By Type - Global Metastatic Cancer Drug Revenue, 2023-2028
4.2.3 By Type - Global Metastatic Cancer Drug Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Metastatic Cancer Drug Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Specialty Clinics
5.2 By Application - Global Metastatic Cancer Drug Revenue & Forecasts
5.2.1 By Application - Global Metastatic Cancer Drug Revenue, 2017-2022
5.2.2 By Application - Global Metastatic Cancer Drug Revenue, 2023-2028
5.2.3 By Application - Global Metastatic Cancer Drug Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Metastatic Cancer Drug Market Size, 2021 & 2028
6.2 By Region - Global Metastatic Cancer Drug Revenue & Forecasts
6.2.1 By Region - Global Metastatic Cancer Drug Revenue, 2017-2022
6.2.2 By Region - Global Metastatic Cancer Drug Revenue, 2023-2028
6.2.3 By Region - Global Metastatic Cancer Drug Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Metastatic Cancer Drug Revenue, 2017-2028
6.3.2 US Metastatic Cancer Drug Market Size, 2017-2028
6.3.3 Canada Metastatic Cancer Drug Market Size, 2017-2028
6.3.4 Mexico Metastatic Cancer Drug Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Metastatic Cancer Drug Revenue, 2017-2028
6.4.2 Germany Metastatic Cancer Drug Market Size, 2017-2028
6.4.3 France Metastatic Cancer Drug Market Size, 2017-2028
6.4.4 U.K. Metastatic Cancer Drug Market Size, 2017-2028
6.4.5 Italy Metastatic Cancer Drug Market Size, 2017-2028
6.4.6 Russia Metastatic Cancer Drug Market Size, 2017-2028
6.4.7 Nordic Countries Metastatic Cancer Drug Market Size, 2017-2028
6.4.8 Benelux Metastatic Cancer Drug Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Metastatic Cancer Drug Revenue, 2017-2028
6.5.2 China Metastatic Cancer Drug Market Size, 2017-2028
6.5.3 Japan Metastatic Cancer Drug Market Size, 2017-2028
6.5.4 South Korea Metastatic Cancer Drug Market Size, 2017-2028
6.5.5 Southeast Asia Metastatic Cancer Drug Market Size, 2017-2028
6.5.6 India Metastatic Cancer Drug Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Metastatic Cancer Drug Revenue, 2017-2028
6.6.2 Brazil Metastatic Cancer Drug Market Size, 2017-2028
6.6.3 Argentina Metastatic Cancer Drug Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Metastatic Cancer Drug Revenue, 2017-2028
6.7.2 Turkey Metastatic Cancer Drug Market Size, 2017-2028
6.7.3 Israel Metastatic Cancer Drug Market Size, 2017-2028
6.7.4 Saudi Arabia Metastatic Cancer Drug Market Size, 2017-2028
6.7.5 UAE Metastatic Cancer Drug Market Size, 2017-2028
7 Players Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Corporate Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Metastatic Cancer Drug Major Product Offerings
7.1.4 AstraZeneca Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.1.5 AstraZeneca Key News
7.2 Merck
7.2.1 Merck Corporate Summary
7.2.2 Merck Business Overview
7.2.3 Merck Metastatic Cancer Drug Major Product Offerings
7.2.4 Merck Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.2.5 Merck Key News
7.3 Pfizer
7.3.1 Pfizer Corporate Summary
7.3.2 Pfizer Business Overview
7.3.3 Pfizer Metastatic Cancer Drug Major Product Offerings
7.3.4 Pfizer Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.3.5 Pfizer Key News
7.4 Celgene
7.4.1 Celgene Corporate Summary
7.4.2 Celgene Business Overview
7.4.3 Celgene Metastatic Cancer Drug Major Product Offerings
7.4.4 Celgene Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.4.5 Celgene Key News
7.5 AKRON
7.5.1 AKRON Corporate Summary
7.5.2 AKRON Business Overview
7.5.3 AKRON Metastatic Cancer Drug Major Product Offerings
7.5.4 AKRON Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.5.5 AKRON Key News
7.6 Novartis
7.6.1 Novartis Corporate Summary
7.6.2 Novartis Business Overview
7.6.3 Novartis Metastatic Cancer Drug Major Product Offerings
7.6.4 Novartis Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.6.5 Novartis Key News
7.7 Galen
7.7.1 Galen Corporate Summary
7.7.2 Galen Business Overview
7.7.3 Galen Metastatic Cancer Drug Major Product Offerings
7.7.4 Galen Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.7.5 Galen Key News
7.8 Pacira BioSciences
7.8.1 Pacira BioSciences Corporate Summary
7.8.2 Pacira BioSciences Business Overview
7.8.3 Pacira BioSciences Metastatic Cancer Drug Major Product Offerings
7.8.4 Pacira BioSciences Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.8.5 Pacira BioSciences Key News
7.9 Johnson & Johnson
7.9.1 Johnson & Johnson Corporate Summary
7.9.2 Johnson & Johnson Business Overview
7.9.3 Johnson & Johnson Metastatic Cancer Drug Major Product Offerings
7.9.4 Johnson & Johnson Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.9.5 Johnson & Johnson Key News
7.10 Fresenius Kabi AG
7.10.1 Fresenius Kabi AG Corporate Summary
7.10.2 Fresenius Kabi AG Business Overview
7.10.3 Fresenius Kabi AG Metastatic Cancer Drug Major Product Offerings
7.10.4 Fresenius Kabi AG Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.10.5 Fresenius Kabi AG Key News
7.11 Spectrum Pharmaceuticals
7.11.1 Spectrum Pharmaceuticals Corporate Summary
7.11.2 Spectrum Pharmaceuticals Business Overview
7.11.3 Spectrum Pharmaceuticals Metastatic Cancer Drug Major Product Offerings
7.11.4 Spectrum Pharmaceuticals Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.11.5 Spectrum Pharmaceuticals Key News
7.12 Takeda Pharmaceutical
7.12.1 Takeda Pharmaceutical Corporate Summary
7.12.2 Takeda Pharmaceutical Business Overview
7.12.3 Takeda Pharmaceutical Metastatic Cancer Drug Major Product Offerings
7.12.4 Takeda Pharmaceutical Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.12.5 Takeda Pharmaceutical Key News
7.13 Teva Pharmaceutical Industries
7.13.1 Teva Pharmaceutical Industries Corporate Summary
7.13.2 Teva Pharmaceutical Industries Business Overview
7.13.3 Teva Pharmaceutical Industries Metastatic Cancer Drug Major Product Offerings
7.13.4 Teva Pharmaceutical Industries Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.13.5 Teva Pharmaceutical Industries Key News
7.14 Cipla
7.14.1 Cipla Corporate Summary
7.14.2 Cipla Business Overview
7.14.3 Cipla Metastatic Cancer Drug Major Product Offerings
7.14.4 Cipla Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.14.5 Cipla Key News
7.15 Sun Pharmaceutical Industries
7.15.1 Sun Pharmaceutical Industries Corporate Summary
7.15.2 Sun Pharmaceutical Industries Business Overview
7.15.3 Sun Pharmaceutical Industries Metastatic Cancer Drug Major Product Offerings
7.15.4 Sun Pharmaceutical Industries Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.15.5 Sun Pharmaceutical Industries Key News
7.16 Shanghai Fosun Pharmaceutical
7.16.1 Shanghai Fosun Pharmaceutical Corporate Summary
7.16.2 Shanghai Fosun Pharmaceutical Business Overview
7.16.3 Shanghai Fosun Pharmaceutical Metastatic Cancer Drug Major Product Offerings
7.16.4 Shanghai Fosun Pharmaceutical Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.16.5 Shanghai Fosun Pharmaceutical Key News
7.17 Ingenus
7.17.1 Ingenus Corporate Summary
7.17.2 Ingenus Business Overview
7.17.3 Ingenus Metastatic Cancer Drug Major Product Offerings
7.17.4 Ingenus Metastatic Cancer Drug Revenue in Global Market (2017-2022)
7.17.5 Ingenus Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Metastatic Cancer Drug Market Opportunities & Trends in Global Market
Table 2. Metastatic Cancer Drug Market Drivers in Global Market
Table 3. Metastatic Cancer Drug Market Restraints in Global Market
Table 4. Key Players of Metastatic Cancer Drug in Global Market
Table 5. Top Metastatic Cancer Drug Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Metastatic Cancer Drug Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Metastatic Cancer Drug Revenue Share by Companies, 2017-2022
Table 8. Global Companies Metastatic Cancer Drug Product Type
Table 9. List of Global Tier 1 Metastatic Cancer Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Metastatic Cancer Drug Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Metastatic Cancer Drug Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Metastatic Cancer Drug Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Metastatic Cancer Drug Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Metastatic Cancer Drug Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Metastatic Cancer Drug Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Metastatic Cancer Drug Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Metastatic Cancer Drug Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Metastatic Cancer Drug Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Metastatic Cancer Drug Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Metastatic Cancer Drug Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Metastatic Cancer Drug Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Metastatic Cancer Drug Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Metastatic Cancer Drug Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Metastatic Cancer Drug Revenue, (US$, Mn), 2023-2028
Table 30. AstraZeneca Corporate Summary
Table 31. AstraZeneca Metastatic Cancer Drug Product Offerings
Table 32. AstraZeneca Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 33. Merck Corporate Summary
Table 34. Merck Metastatic Cancer Drug Product Offerings
Table 35. Merck Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 36. Pfizer Corporate Summary
Table 37. Pfizer Metastatic Cancer Drug Product Offerings
Table 38. Pfizer Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 39. Celgene Corporate Summary
Table 40. Celgene Metastatic Cancer Drug Product Offerings
Table 41. Celgene Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 42. AKRON Corporate Summary
Table 43. AKRON Metastatic Cancer Drug Product Offerings
Table 44. AKRON Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 45. Novartis Corporate Summary
Table 46. Novartis Metastatic Cancer Drug Product Offerings
Table 47. Novartis Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 48. Galen Corporate Summary
Table 49. Galen Metastatic Cancer Drug Product Offerings
Table 50. Galen Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 51. Pacira BioSciences Corporate Summary
Table 52. Pacira BioSciences Metastatic Cancer Drug Product Offerings
Table 53. Pacira BioSciences Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 54. Johnson & Johnson Corporate Summary
Table 55. Johnson & Johnson Metastatic Cancer Drug Product Offerings
Table 56. Johnson & Johnson Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 57. Fresenius Kabi AG Corporate Summary
Table 58. Fresenius Kabi AG Metastatic Cancer Drug Product Offerings
Table 59. Fresenius Kabi AG Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 60. Spectrum Pharmaceuticals Corporate Summary
Table 61. Spectrum Pharmaceuticals Metastatic Cancer Drug Product Offerings
Table 62. Spectrum Pharmaceuticals Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 63. Takeda Pharmaceutical Corporate Summary
Table 64. Takeda Pharmaceutical Metastatic Cancer Drug Product Offerings
Table 65. Takeda Pharmaceutical Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 66. Teva Pharmaceutical Industries Corporate Summary
Table 67. Teva Pharmaceutical Industries Metastatic Cancer Drug Product Offerings
Table 68. Teva Pharmaceutical Industries Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 69. Cipla Corporate Summary
Table 70. Cipla Metastatic Cancer Drug Product Offerings
Table 71. Cipla Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 72. Sun Pharmaceutical Industries Corporate Summary
Table 73. Sun Pharmaceutical Industries Metastatic Cancer Drug Product Offerings
Table 74. Sun Pharmaceutical Industries Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 75. Shanghai Fosun Pharmaceutical Corporate Summary
Table 76. Shanghai Fosun Pharmaceutical Metastatic Cancer Drug Product Offerings
Table 77. Shanghai Fosun Pharmaceutical Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
Table 78. Ingenus Corporate Summary
Table 79. Ingenus Metastatic Cancer Drug Product Offerings
Table 80. Ingenus Metastatic Cancer Drug Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Metastatic Cancer Drug Segment by Type in 2021
Figure 2. Metastatic Cancer Drug Segment by Application in 2021
Figure 3. Global Metastatic Cancer Drug Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Metastatic Cancer Drug Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Metastatic Cancer Drug Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Metastatic Cancer Drug Revenue in 2021
Figure 8. By Type - Global Metastatic Cancer Drug Revenue Market Share, 2017-2028
Figure 9. By Application - Global Metastatic Cancer Drug Revenue Market Share, 2017-2028
Figure 10. By Region - Global Metastatic Cancer Drug Revenue Market Share, 2017-2028
Figure 11. By Country - North America Metastatic Cancer Drug Revenue Market Share, 2017-2028
Figure 12. US Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Metastatic Cancer Drug Revenue Market Share, 2017-2028
Figure 16. Germany Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 17. France Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Metastatic Cancer Drug Revenue Market Share, 2017-2028
Figure 24. China Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 28. India Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Metastatic Cancer Drug Revenue Market Share, 2017-2028
Figure 30. Brazil Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Metastatic Cancer Drug Revenue Market Share, 2017-2028
Figure 33. Turkey Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Metastatic Cancer Drug Revenue, (US$, Mn), 2017-2028
Figure 37. AstraZeneca Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Merck Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Pfizer Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Celgene Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. AKRON Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Novartis Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Galen Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Pacira BioSciences Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Johnson & Johnson Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Fresenius Kabi AG Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Spectrum Pharmaceuticals Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Takeda Pharmaceutical Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Teva Pharmaceutical Industries Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Cipla Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Sun Pharmaceutical Industries Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Shanghai Fosun Pharmaceutical Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Ingenus Metastatic Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
